Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1981 to 1995 of 2172 results for technology appraisal

  1. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]

    In development Reference number: GID-TA11624 Expected publication date: TBC

  2. Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]

    In development Reference number: GID-TA11709 Expected publication date: TBC

  3. Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]

    In development Reference number: GID-TA11781 Expected publication date: TBC

  4. Belatacept for the prevention of organ rejection in kidney transplantation [ID87]

    Discontinued Reference number: GID-TAG239

  5. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  6. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

  7. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development Reference number: GID-TA11157 Expected publication date: TBC

  8. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    Discontinued Reference number: GID-HST10032

  9. Daridorexant for treating long-term insomnia (TA922)

    Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.

  10. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued Reference number: GID-TA10099

  11. NICE's prioritisation process explained – what healthtech developers need to know

    Understand why we're prioritising key topic areas for evaluation and what it means for innovators

  12. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued Reference number: GID-TA10065

  13. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113

    In development Reference number: GID-TA11025 Expected publication date: TBC

  14. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.